机构：[1]Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China重点科室诊疗科室神经病学中心首都医科大学附属天坛医院[2]China National Clinical Research Center for Neurological Diseases, Beijing, China[3]Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China[4]Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
Objectives: Statin use during hospitalization improves prognosis in patients with ischaemic stroke. However, it remains uncertain whether acute ischaemic stroke patients with chronic kidney disease (CKD) benefit from statin therapy. We investigated the effect of statin use during hospitalization in reducing short-term mortality of patients with ischaemic stroke and CKD. Methods: Data of first-ever ischaemic stroke patients without a history of pre-stroke statin treatment was derived from the China National Stroke Registry. Patients were stratified according to estimated glomerular filtration rate (eGFR): normal renal function (eGFR X90 mL/min/1.73 m(2)), mild CKD (eGFR 60-90 mUmin/1.73 m(2)) and moderate CKD (eGFR <60 mUmin/1.73 m(2)). Multivariate logistic regression analysis was used to evaluate the association between statin use during hospitalization and all-cause mortality with different renal functions at 3-month follow-up. Results: Among 5,951 patients included, 2,595 (43.6%) patients were on statin use during hospitalization after stroke (45.7% in patients with normal renal function, 42.0% in patients with mild CKD, and 39.0% in patients with moderate CKD). Compared with the non-statin group, statin use during hospitalization was associated with decreased allcause mortality in patients with normal renal function (OR 0.65, 95% CI 0.43-0.97, p = 0.04), mild CKD (OR 0.59, 95% CI 0.38-0.91, p=0.02) and moderate CKD (OR 0.41, 95%CI 0.230.75, p = 0.004) at 3-month follow-up. Conclusions: Statin use during hospitalization was associated with decreased 3-month mortality of ischaemic stroke patients with mild and moderate CKD. However, the conclusion should be confirmed in further studies with larger population, especially with moderate CKD. (C) 2018 S. Karger AG, Basel
基金：
National Key Technology Research and Development Program of the Ministry of Science and Technology of the People's Republic of China [2015BAI12B04, 2015BAI12B02]; Beijing Municipal Administration of Hospitals [SML20150502]
第一作者机构：[1]Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[2]China National Clinical Research Center for Neurological Diseases, Beijing, China[3]Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China[4]Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China
通讯作者：
通讯机构：[1]Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China[2]China National Clinical Research Center for Neurological Diseases, Beijing, China[3]Center of Stroke, Beijing Institute for Brain Disorders, Beijing, China[4]Beijing Key Laboratory of Translational Medicine for Cerebrovascular Disease, Beijing, China[*1]Department of Neurology, Beijing Tiantan Hospital, Capital Medical University No. 6 Tiantanxili, Dongcheng District Beijing 100050 (China)
推荐引用方式(GB/T 7714)：
Zhang Xinmiao,Jing Jing,Zhao Xingquan,et al.Statin Use during Hospitalization and Short-Term Mortality in Acute Ischaemic Stroke with Chronic Kidney Disease[J].EUROPEAN NEUROLOGY.2018,79(5-6):296-302.doi:10.1159/000488402.
APA：
Zhang, Xinmiao,Jing, Jing,Zhao, Xingquan,Liu, Liping,Wang, Chunxue...&Wang, Yongjun.(2018).Statin Use during Hospitalization and Short-Term Mortality in Acute Ischaemic Stroke with Chronic Kidney Disease.EUROPEAN NEUROLOGY,79,(5-6)
MLA：
Zhang, Xinmiao,et al."Statin Use during Hospitalization and Short-Term Mortality in Acute Ischaemic Stroke with Chronic Kidney Disease".EUROPEAN NEUROLOGY 79..5-6(2018):296-302
